date:Feb 25, 2019
astatin has recently been cited in some press accounts. Looking at this drug as an example, the FDA pharmacovigilance experts reviewed data from our FAERS database along with drug utilization data from January 1, 2012 through December 31, 2018 and did not find evidence that any single generic atorvastatin was more likely to be associated with adverse events than another (or that any generic was more likely to be associated with adverse events than the innovator product).
The FDA has no concerns